Hong Kong-based AI-driven company sells potential breast cancer drug in deal whose value could exceed US$500 million

Stemline Therapeutics, a wholly-owned unit of Menarini Group, will make a US$12 million upfront payment to Insilico under the agreement, which will be followed by sales royalties worth up to ‘double digits’.

Related Keywords

Canada ,China ,Hong Kong ,Saudi Arabia ,New York ,United States ,Qiming ,Sichuan ,Elcin Barker Ergun ,Alex Zhavoronkov ,Abu Dhabi ,Warburg Pincus ,Precedence Research ,Quantum Computing Research ,World Health Organization ,B Capital Group ,Development Center ,Vantage Market Research ,Vantage Market ,World Health ,Greater China ,Hong Kong Based Qiming ,Insilico Medicine ,Menarini Group ,Temline ,Prosperity7 ,Qiming Ventures ,